Lupron Depot

DRUG4 trials

Sponsors

Repros Therapeutics Inc., GTx, University of Michigan Rogel Cancer Center, Ottawa Hospital Research Institute

Conditions

Prostate CancerUterine Fibroids

Phase 2

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

TerminatedNCT00683917

Repros Therapeutics Inc.Uterine Fibroids

Start: 2008-05-31End: 2009-08-31Updated: 2014-08-21

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

TerminatedNCT01326312

GTxProstate Cancer

Start: 2011-06-30End: 2012-12-31Updated: 2023-06-22

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

CompletedNCT02059213

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2014-06-30End: 2019-06-04Updated: 2020-09-16

Phase 3

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

RecruitingNCT05169112

Ottawa Hospital Research InstituteProstate Cancer

Start: 2023-03-06End: 2028-11-30Target: 72Updated: 2025-03-20

Related Papers

Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2020-05-207 citations

Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2018-02-205 citations

Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2017-02-20

Abstract IA06: Co-Targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer

Molecular Cancer Research2016-11-01

A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology2015-05-201 citations